Cerus (CERS) Cantor Global Healthcare Conference 2025 summary

Company overview and mission

• Focused on transforming transfusion medicine by making INTERCEPT Blood Systems the global standard of care.

• Founded in the early 1990s to safeguard blood components during the HIV and hepatitis epidemics.

• Products are now commercialized in over 40 countries, with significant untapped market potential.

• Mission-driven to ensure real-time access to safe blood for patients worldwide.

Financial performance and outlook

• Achieved 16% year-over-year growth and raised revenue guidance to $200M–$203M.

• IFC product guidance increased to $16M–$18M, nearly doubling its profile.

• Operating cash flow expected to be positive for the full year, with improved margins and leverage on SG&A and R&D.

• Five consecutive quarters of positive adjusted EBITDA, aiming for a second straight year.

Product innovation and market expansion

• INTERCEPT Fibrinogen Complex (IFC) offers a five-day shelf life and immediate availability for major bleeding events.

• IFC is primarily focused on the U.S. market, with future plans for ex-U.S. expansion, especially Asia-Pacific.

• INTERCEPT platelets have 65%-70% penetration in the U.S., with further growth expected as new technologies launch.

• Ex-U.S. platelet adoption varies, with some countries at 100% and others just beginning.